Literature DB >> 30536306

Downregulation of miR-1294 associates with prognosis and tumor progression in epithelial ovarian cancer.

T-Y Guo1, H-Y Xu, W J Chen, M-X Wu, X Dai.   

Abstract

OBJECTIVE: Increasing evidence has revealed that microRNAs (miRNAs) act as key players in the regulation of tumor growth and metastasis in epithelial ovarian cancer (EOC). However, the clinical role and functional effects of miR-1294 in EOC remain unknown. PATIENTS AND METHODS: We examined the expression of miR-1294 in 69 cases of EOC tissues and cell lines by quantitative Real-time polymerase chain reaction (qRT-PCR). The associations of miR-1294 expression with clinicopathologic features and overall survival of EOC patients were analyzed. Biological functional effects of miR-1294 expression on cell growth were analyzed using Cell Counting Kit-8 (CCK8) assays and flow cytometry assays in vitro.
RESULTS: In the present study, we identified that miR-1294 expression was lower in 76 specimens of EOC compared to adjacent normal tissues. Lower miR-1294 expression was related to FIGO stage, lymph node metastasis and shorter overall survival rate in EOC patients. Multivariate Cox analysis demonstrated that miR-1294 expression was an independent prognostic indicator of EOC patients. Gain function assays showed that miR-1294 overexpression inhibited cell proliferation and cell cycle progression in EOC.
CONCLUSIONS: Our results indicated that miR-1294 acted as a prognostic biomarker and potential target of EOC treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536306     DOI: 10.26355/eurrev_201811_16381

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway.

Authors:  Wenchang Liang; Cailing Wang; Junsheng Wang; Mingzhi Zhang
Journal:  Appl Biochem Biotechnol       Date:  2022-05-06       Impact factor: 3.094

2.  Circ_0000885 Enhances Osteosarcoma Progression by Increasing FGFR1 Expression via Sponging MiR-1294.

Authors:  Yinxian Chen; Sicheng Zhang; Chuanqing Bai; Zhiye Guan; Wenjian Chen
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

Review 3.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

4.  Identification of dysregulated miRNAs-genes network in ovarian cancer: An integrative approach to uncover the molecular interactions and oncomechanisms.

Authors:  Sepideh Kadkhoda; Farzaneh Darbeheshti; Javad Tavakkoly-Bazzaz
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-04

5.  CircCDK17 knockdown inhibits tumor progression and cell glycolysis by downregulaing YWHAZ expression through sponging miR-1294 in cervical cancer.

Authors:  Rui Chen; Fei Liang; Jun Yan; Yu Wang
Journal:  J Ovarian Res       Date:  2022-02-15       Impact factor: 4.234

6.  [MiR-300 inhibits invasion and metastasis of osteosarcoma cell MG63 by negatively regulating PTTG1].

Authors:  D Liang; X Wu; J Bai; L Zhang; C Yin; W Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-02-25

Review 7.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

8.  miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A.

Authors:  Fang Xiao; Songshu Xiao; Min Xue
Journal:  Onco Targets Ther       Date:  2019-12-06       Impact factor: 4.147

9.  Antitumor Effect of miR-1294/Pyruvate Kinase M2 Signaling Cascade in Osteosarcoma Cells.

Authors:  Quan Yuan; Honghao Yu; Jianhua Chen; Xiaoyu Song; Li Sun
Journal:  Onco Targets Ther       Date:  2020-02-21       Impact factor: 4.147

Review 10.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.